COMELEC SA

Their core work

COMELEC SA is a Swiss precision electronics SME based in La Chaux-de-Fonds — a city historically synonymous with miniaturized, high-tolerance manufacturing through its watchmaking industry. Their H2020 participation in two medical device pilot-line projects points to a specialist role in the micro-fabrication and electronic assembly of miniaturized medical components. Their second project, POSITION-II, places them firmly in the cardiovascular interventional space: smart catheters, intravascular ultrasound (IVUS), fractional flow reserve (FFR) measurement tools, intracardiac echocardiography (ICE), and implantable devices used in catheterization laboratories. The small EC funding received relative to two full project participations suggests they contribute a precise, component-level capability — likely electronic sub-assemblies, micro-connectors, or sensor integration — within large industrial manufacturing consortia.

What they specialise in

How they've shifted over time

In their first H2020 engagement (InForMed, 2015–2018), COMELEC worked on a broad micro-fabricated medical device pilot line, with no recorded keyword specialization — suggesting a general manufacturing contribution to shared fabrication infrastructure. By the time of POSITION-II (2018–2021), their documented focus had narrowed significantly to the cardiovascular interventional domain: smart catheters, cath lab equipment, and implantable devices with specific diagnostic modalities (IVUS, FFR, ICE). This shift from general micro-fabrication capacity toward a defined cardiology device niche represents a deliberate or market-driven deepening of specialization over a six-year window.

COMELEC is converging on cardiovascular interventional devices as its core application niche, making them a relevant manufacturing partner for any consortium developing next-generation cath lab tools or minimally invasive cardiac implants.

How they like to work

COMELEC has participated exclusively as a consortium partner — never as coordinator — across both H2020 projects, signaling that they contribute specialist manufacturing capability rather than project leadership or consortium management. Both participations were in large-scale pilot-line projects under ECSEL-IA and IA funding schemes, which typically involve 20–50+ partners; the 69 unique partners logged across just two projects confirms they are experienced operating as one specialist node within complex, multi-country industrial networks. Organizations considering them as partners should expect a reliable technical contributor rather than a consortium driver.

Across only two projects, COMELEC has accumulated 69 unique consortium partners in 13 countries — a footprint that reflects the large-scale, multi-actor structure of ECSEL and IA pilot-line consortia rather than a broad independent outreach strategy. Their network is pan-European with no evident geographic concentration beyond their Swiss base.

What sets them apart

COMELEC's most distinctive asset is its location in La Chaux-de-Fonds, the historical center of Swiss watchmaking — an industry built entirely on extreme miniaturization, tight tolerances, and precision assembly at scale. That manufacturing DNA, applied to medical micro-fabrication, positions them differently from electronics firms in industrial or automotive regions where tolerances are measured in millimeters rather than microns. Their track record on EU pilot lines — rather than academic research projects — means they understand the demands of moving from prototype to manufacturable product, which is where most medical device development programs stall.

Highlights from their portfolio

• POSITION-II
  Defines COMELEC's cardiovascular niche most precisely — the only project with full keyword data, covering smart catheters, IVUS, FFR, ICE, and implantables, making it the primary evidence base for their clinical device manufacturing capabilities.
• InForMed
  Their entry point into European medical device manufacturing consortia, establishing their role in micro-fabrication pilot line infrastructure before the application domain had narrowed to cardiology.